Clinical Trials Directory

Trials / Unknown

UnknownNCT03995251

Efficacy and Safety of Testosterone Therapy in Improving Sarcopenia in Men With Cirrhosis.

Efficacy and Safety of Testosterone Therapy in Improving Sarcopenia in Men With Cirrhosis a Randomized Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Institute of Liver and Biliary Sciences, India · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

* Study Population- Patient with cirrhosis with any aetiology with sarcopenia visiting ILBS OPD/IPDs who are willing to visit ILBS gymnasium twice weekly for first month. * Study Design- A Prospective Randomized Controlled Trial * Study Period- Study will be conducted at ILBS from April 2019 to Oct 2019 * Sample Size:As shown by Eva Roman et al - in cirhotics with sarcopenia exercise increases mean lean appendicular mass , by 0.38 kg (14 patients, p \< 0.03), and Sinclair et al has shown testosterone (22 patients, p \<0.05)) to increase mean Appendicular lean mass by +1.69 kg - for 10% increase in APLM * we need to enroll 40 patients in each arm, and considering a los to follow up approx.10% , will require minimum 44 patients in each arm * We will therefore enroll and randomize 100 patients with 50 in each arm. Intervention - Testosterone Supplementation - Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations. Monitoring and assessment - On every visit patient will be inquired or evaluated for side effects like local site pain or hematoma , hypertension, headache, allergic reactions, acne, nausea , mood swings, pedal edema , breast enlargement and others.

Conditions

Interventions

TypeNameDescription
DRUGTestosterone SupplementationIntramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
DRUGStandard Medical TreatmentStandard Medical Treatment
OTHERExerciseExercise

Timeline

Start date
2019-07-04
Primary completion
2020-06-30
Completion
2020-06-30
First posted
2019-06-24
Last updated
2019-08-21

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT03995251. Inclusion in this directory is not an endorsement.